Objective

Evaluate the antiproliferative, antibacterial and anti-inflammatory properties of Myrtacine® and its active molecules, myrtucommulones A and B, in in vitro models.

Myrtacine® is an ethanolic extract of Myrtus communis leaves, patented by Pierre Fabre Laboratories

Methodology 

• Antiproliferative activity: in vitro culture of human keratinocytes in the presence of Myrtacine®, Myrtucommulones A and B, growth factor (positive control) or without addition (negative control)
• Antibacterial activity: measurement of the Minimum Inhibitory Concentration (MIC) of Myrtacine® and myrtucommulones A and B on erythromycin-sensitive and -resistant strains of Propionibacterium acnes (EryS and EryR), after 5, 10, 30 and 60 minutes of incubation
• Anti-inflammatory activity: measuring the effect of Myrtacine® on cyclooxygenase and lipoxygenase activity 

Results

• Antiproliferative activity: Myrtacine® and myrtucommulones A and B have significant dose-dependent antiproliferative activity on keratinocytes
• Antibacterial activity: Myrtacine® and myrtucommulones A and B have significant time-dependent antibacterial activity on erythromycin-sensitive and -resistant P. acnes strains
• Anti-inflammatory activity: Myrtacine® has a significant inhibitory effect on cyclooxygenase and lipoxygenase activity 

Conclusion

Myrtacine® has proven its value in the treatment of non-inflammatory and inflammatory acne thanks to its antiproliferative, antibacterial and anti-inflammatory properties